In addition, patients present with triple-negative breast cancer (TNBC) and those with hormone receptor-negative (HR-) and HER2-positive (HER2 +) tumors often exhibit a better response to NAC [6, 7]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.